[144] Century Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Century Therapeutics (IPSC) filed a Form 144 reporting a proposed sale of 488 shares of common stock through Fidelity Brokerage Services with an aggregate market value of $243.95. The shares were acquired on 09/05/2025 as a restricted stock vesting event and payment is listed as compensation. The filer indicates the approximate date of sale as 09/08/2025 and cites NASDAQ as the exchange. The filing also discloses two sales by the same person in the past three months: 475 shares sold on 06/09/2025 for $295.50 and 30,745 shares sold on 08/18/2025 for $17,521.58. The notice includes the standard representation that the seller has no undisclosed material adverse information.

Positive

• Transparent disclosure of the proposed sale details including broker, share count, and aggregate market value
• Acquisition nature disclosed as restricted stock vesting with payment listed as compensation
• Prior sales fully listed with dates and gross proceeds for the past three months

Negative

• None.

Insights

Securities Analyst

TL;DR Form 144 reports a small proposed sale of vested restricted shares and discloses recent insider sales totaling 31,220 shares.

The filing shows a proposed disposition of 488 vested shares via Fidelity with a low aggregate value ($243.95), indicating this particular sale is modest in absolute dollar terms. The filing also documents two prior sales within three months totaling 31,220 shares, generating $17,817.08 in gross proceeds. From a compliance standpoint, the notice follows Rule 144 reporting requirements and includes the seller's certification about undisclosed material information. No forward-looking statements or additional company financial data are provided.

Corporate Governance Expert

TL;DR Disclosure meets procedural requirements; seller attests to no undisclosed material information and identifies restricted stock vesting.

The form specifies the nature of acquisition as restricted stock vesting and identifies compensation as the payment type, clarifying that these shares originated from an issuer grant rather than open-market purchase. The record of sales in the prior three months is transparent and includes dates and gross proceeds. The filing contains no additional governance issues, litigation notes, or exceptions; it is a routine Rule 144 compliance filing based solely on the data presented.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	488	243.95	86389098	09/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/05/2025	Restricted Stock Vesting	Issuer			488	09/05/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Brent G. Pfeiffenberger 25 N 38th Street 11th Floor Philadelphia PA 19104	Common	06/09/2025	475	295.50
Brent G. Pfeiffenberger 25 N 38th Street 11th Floor Philadelphia PA 19104	Common	08/18/2025	30745	17521.58

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Century Therapeutics' (IPSC) Form 144 report?

The filing reports a proposed sale of 488 common shares through Fidelity, acquired via restricted stock vesting on 09/05/2025, with an approximate sale date of 09/08/2025.

How much is the aggregate market value of the shares to be sold?

The aggregate market value reported for the 488 shares is $243.95.

Were there insider sales by the same person recently?

Yes. The filer sold 475 shares on 06/09/2025 for $295.50 and 30,745 shares on 08/18/2025 for $17,521.58 in the past three months.

What was the nature of how the 488 shares were acquired?

The shares were acquired on 09/05/2025 through restricted stock vesting from the issuer, listed as compensation.

Which broker is handling the proposed sale?

The proposed sale lists Fidelity Brokerage Services LLC as the broker.